Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FKKF3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The award was issued on December 9, 2025, with an ultimate completion date of December 31, 2025, under a firm fixed-price contract structure with no set-aside designation. This delivery order is issued pursuant to DMS Pharmaceutical Group's single-award Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and extends through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply across the Department of Defense's global military healthcare operations. Under this broader vehicle, DMS Pharmaceutical Group serves as a critical regional prime vendor contractor authorized to fulfill diverse and specialized pharmaceutical requirements, including branded and generic prescription medications, biologics, vaccines, and medical consumables. Stelara, an immunosuppressant biologic agent, falls within the company's established product portfolio of specialty pharmaceuticals that support DoD healthcare facilities worldwide. The company's demonstrated performance on numerous prior delivery orders and its status as a certified woman-owned small business position it as a qualified supplier within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FKKF3?
SPE2DR26FKKF3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FKKF3 worth?
The government has obligated $16,584 on SPE2DR26FKKF3.
Is contract SPE2DR26FKKF3 an order under another contract?
Yes. SPE2DR26FKKF3 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKF3 competed?
The extent of competition for SPE2DR26FKKF3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award